Lung Cancer Clinical Trials
CRB-701
A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, and Efficacy of CRB-701, an
Antibody-drug Conjugate Targeting Nectin-4, in Patients with Advanced Solid Tumors
AB598
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
GEN1042
A First-in-Human, Open-label, Dose-escalation Trial with Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects with Malignant Solid Tumors
TEMPUS GEMINI NSCLC STUDY
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Non-Small Cell Lung Cancer (NSCLC)
Pfizer C5751003
An Open-Label, Randomized, Controlled Phase 3 Study Of Sigvotatug Vedotin In Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy As First-Line Treatment In Participants With Pd-L1 High (≥50% Of Tumor Cells Expressing Pd-L1), Locally Advanced, Unresectable, Or Metastatic Non-Small Cell Lung Cancer (Be6a Lung-02)
Gilead
A Global, Multicenter, Randomized, Open-label, Phase 3 study of Sacituzumab Govitecan versus Standard of Care (SoC) in Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC).
COCOON
A Phase 2, Open-Label, Randomized Trial Evaluating Enhanced Versus Standard Dermatologic Management for Selected Dermatologic Adverse Events in Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC Treated First-Line With Amivantamab Plus Lazertinib
ARTEMIDE Lung 02_D702BC00001
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
ARTEMIDE Lung 03
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)
TROPION Lung 10
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig (AZD2936) or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
DESTINY-Lung06
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)
Pfizer C6461001
An Interventional Phase 3, Double-Blind, Randomized, Study to Investigate Tolerability, PK and Anti-Tumor Efficacy of PF-08634404 (SSGJ-707) in Combination with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy in Adult Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer” (“Study”) to be conducted at Institution under the Pfizer protocol identified above.